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Background/Objective: This report describes the 2014 consensus of the Taiwanese Dermatological Asso-
ciation (TDA) regarding the treatment of atopic dermatitis (AD). The TDA consensus is distributed to
practices throughout Taiwan to provide recommendations for therapeutic approaches for AD patients to
improve their quality of life.
Methods: The information in the consensus was agreed upon by a panel of national experts at TDA AD
consensus meetings held on March 16, May 4, and June 29, 2014. The consensus was in part based on the
2013 AsiaePaciﬁc AD guidelines and the guidelines of the American Academy of Dermatology, with
modiﬁcation to reﬂect the clinical practice in Taiwan.
Results: The amendments were drafted after scientiﬁc discussions focused on the quality of evidence,
risk, and beneﬁts; all the consensus contents were voted on by the participating dermatologists, with
approval by at least 75% for inclusion.
Conclusion: The consensus provides a comprehensive overview of treatment for AD, with some local and
cultural considerations for practitioners in Taiwan, especially the use of wet dressings/wraps, systemic
immunomodulatory agents, and complementary therapies.
Copyright © 2015, Taiwanese Dermatological Association.
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Atopic dermatitis (AD) is a common inﬂammatory disease that
appears to have increased in prevalence over the past few de-
cades.1,2 The prevalence of AD in Taiwan is estimated to be
approximately 6.7% based on the National Health Insurance data-
base for 2000e2007.3 More speciﬁcally, the prevalence ranged
from 1.7% to 3.35% in 2002,4,5 but has roughly doubled since then.3,6
From the investigation of The International Study of Asthma andier Taiwan LLC. All rights reserved.
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year age group was increased from 3.5% in phase I to 6.7% in phase
II; in the 13e14 year age group, the prevalence increased from 1.4%
in phase I to 4.1% in phase II.7,8 The increase of prevalence is
especially prominent in teenagers. Although AD is common in
childhood, it may also occur in adulthood. Adult-onset AD is
deﬁned by the ﬁrst appearance of AD symptoms after the age of 20
years.9 Adult-onset AD differs from classical AD by preferentially
affecting the face, hands, and nonﬂexural areas and frequently
presents as a prurigo-like pattern. Early and/or current exposure to
cigarette smokingmay contribute cumulatively to the development
of adult-onset AD.9 AD is a chronic relapsing disease that may last
for several months or years. Family aggregation is commonly
associated with AD,10 and the disease has physiological, psycho-
logical, and social impacts. AD requires a holistic assessment by
healthcare practitioners, and a multidisciplinary, team-based
approach involving dermatologists, general practitioners, pedia-
tricians, respiratory specialists, allergologists, nurses, psychologists,
nutritionists and social workers to provide proper care. Physicians
should focus on the current treatment plan while aiming to
improve overall safety and quality of life.
In Taiwan, the prevalence and impact of atopic dermatitis are
dependent to some extent on various socioeconomic conditions,
varying climates, and patient access to available therapies.3e6 With
those factors in mind, the current treatment consensus has been
developed to provide up-to-date and concise evidence- and
experience-based recommendations directed towards general
practitioners and general dermatologists in Taiwan regarding the
management of pediatric and adult AD. The information in the
consensus was agreed upon by a panel of national experts who
convened at Taiwanese Dermatological Association (TDA) AD
consensus meetings held on March 16, May 4, and June 29, 2014,
with all of the speciﬁc aspects of the content requiring approval by
at least 75% of the experts in attendance.
Materials and methods
Consensus panel
A total of 14 dermatologists recommended by their respective
teaching hospitals across Taiwan and also by the TDA were invited
to serve as the TDA Consensus Panel. The 2013 AsiaePaciﬁc
guidelines and the 2014 American Academy of Dermatology (AAD)
guidelines for the management of AD were provided for the
Consensus Panel,1,11,12 and then a variety of amendments made
speciﬁcally for practitioners in Taiwan were included after discus-
sion during the ﬁrst two of the three consensus meetings. For each
of these amendments, scientiﬁc discussions were conducted on the
quality of evidence (including transparency and clear criteria)
supporting the given amendment, as well as on the risks and
beneﬁts of the recommended practices. Following these discus-
sions, the Consensus Panel proposed a draft of the TDA consensus
for the treatment of AD, and then invited another 17 dermatologists
recommended by 28 teaching hospitals in Taiwan to attend a third
consensus meeting to vote on the ﬁnal version of the consensus. A
total of 27 dermatologists ultimately attended the third meeting.
Consensus voting system
The 27 dermatologist experts attending the third consensus
meeting cast their votes for individual content items by rating their
approval of each item on a scale from 1 to 9, with 1 representing
highly disagreed and 9 representing highly agreed. Statements with
ratings of 7e9 by  75% of the total votes were listed as achieving
consensus. In the event that the original version of an itemwas notapproveddi.e., when ratings of 7e9 accounted for < 75% of all the
votesdpotential amendments to the item were drafted and then
voted upon. Votes on these amendments were conducted on a yes/
no basis, with an agreement rating of > 50% required for imple-
mentation. If an amendment to an item was approved, the amen-
ded item was then voted on again using the 1e9 scale, with
approval again contingent upon ratings of 7e9 accounting for 
75% of the votes. When ratings of 7e9 for an amended item
accounted for < 75% of the votes, or when no votes for an amend-
ment itself accounted for  50% of the votes, a different amend-
ment to the itemwas voted upon. In this way, each itemwas either
approved in its original form or in some amended form.
Results
The consensus recommendations stratiﬁed by different lines of
treatments for AD were approved by the participants with ratings
of 7e9 accounted for 84% of the total votes cast (Table 1). The ﬁrst
line treatments include emollients, topical corticosteroids (TCSs),
antihistamines and therapeutic patient education; the second line
treatments include topical calcineurin inhibitors (TCIs), burst use of
systemic corticosteroids, phototherapy, and topical/systemic anti-
biotics, while the third line treatments include systemic immuno-
modulatory agents, antiseptics, and alternative medicine. The use
of emollients and TCSs both obtained 100% of the participants
rating 7e9 (Tables 2 and 3), antihistamines were agreed by 96% of
the participants (Table 4), and therapeutic patient education was
approved by 100% of the experts (Table 5). Among the second line
treatments, the percentages of rating 7-9 by the participated ex-
perts were TCIs 100% (Table 6), burst use of systemic corticosteroids
96% (Table 7), phototherapy 100% (Table 8), and topical/systemic
antibiotics 100% (Table 9). The consensus recommendations of
systemic immunodulatory treatments for AD were approved by the
95.6% of participants (ratings of 7e9; Table 10), while the consensus
recommendations of antiseptics and alternative medicine treat-
ments for AD were approved by 100% and 95.6% of the experts,
respectively (Tables 11 and 12). After conﬁrming these three lines of
treatment, the committee proposed an algorithm of treatment
stratiﬁed by three steps in real practice (Figure 1). The initial
assessment should include a detailed history and extent/severity of
AD, followed by the ﬁrst step of treatment with emollients, thera-
peutic patient education and avoidance of irritants/allergens.When
the disease activity ﬂares acutely, immediate control of pruritus
and inﬂammation by antihistamines and TCSs is recommended. If
the symptoms improve, the Step 2 maintenance therapy such as
TCIs, proactive or intermittent treatment with TCSs could be used. If
the symptoms aggravate after Step 1 treatment, burst use of sys-
temic corticosteroids, phototherapy, or control of infections might
be needed. If these intensive treatments still do not work, the third
step treatments such as systemic immunomodulatory agents,
potent TCSs, aggressive phototherapy, alternative medicine or
psychotherapeutic approach might be helpful. All the patients may
shift to maintenance therapy once the AD symptoms are controlled
after Step 3 treatment or intensive treatment, and they may further




As a barrier between the host and the environment, skin not only
prevents water loss from within, but also protects against external
insults from the environment. Skin barrier function is impaired in
patients with AD, both in the lesional skin and normal looking skin,
Table 1 General overview of the Taiwanese Dermatological Association consensus





 Therapeutic patient education
Second line treatment
 Topical calcineurin inhibitors
 Burst use of systemic corticosteroids
 Phototherapy
 Topical and systemic antibiotics
Third line treatment
 Systemic immunomodulatory agents
 Antiseptics
 Alternative medicine
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decreased water content.13 In particular, ﬁlaggrin is important for
the functional integrity of the skin barrier. Alterations in the ﬁlag-
grin gene, which result in a weakening of the skin barrier, have
been identiﬁed in eczema,14 and evidence indicates that a greaterTable 2 Consensus recommendations for emollients for atopic dermatitis (AD).
 Regular emollient therapy is an essential component in the management strategy o
 Emollients should be applied at least 2 times daily or as frequently as the skin gets
 Ensure adequate quantities are used.
 Emollients may be used during active disease ﬂares in conjunction with topical anti-
bathing while the skin is still moist.
 Fragrances and preservatives in emollient may act as possible irritants.
 The application of moisturizers should be an integral part of the treatment of patients
the need for pharmacologic intervention.
 Bathing is suggested for patients with AD as part of treatment and maintenance; how
those with AD.
 Moisturizers should be applied soon after bathing to improve skin hydration in pati
 Limited use of nonsoap cleansers (that are neutral to low pH, hypoallergenic, and fr
 For the treatment of patients with AD, the addition of oils, emollients, andmost other
at this time, because of insufﬁcient evidence.
 Use of wet-wrap therapy with or without a topical corticosteroid can be recommend
loss during ﬂares.
Table 3 Consensus recommendations for topical corticosteroids (TCSs).
 TCSs are recommended for AD-affected individuals who have failed to respond to go
used appropriately and under adequate supervision. TCSs should be used until skin
 A variety of factors should be considered when choosing a particular TCS for the tr
eczema, areas of the body to which the medication will be applied, and other patien
 Twice-daily application of corticosteroids is generally recommended for the treatm
costeroids may be sufﬁcient.
 Appropriate quantities of TCSs to be used should be discussed with the patient.
 TCSs can be applied to areas of broken skin (e.g. skin with scratch wounds, acute in
 TCSs are not contraindicated in the presence of infection but the infection should b
 Proactive, intermittent use of TCSs as maintenance therapy (1 or 2 times/wk) on a
effective than use of emollients alone.
 The potential for both topical and systemic side effects, including possible hypotha
children with AD in whom corticosteroids are used. Monitoring by physical examin
recommended.
 No speciﬁc monitoring for systemic side effects is routinely recommended for patie
 Patient fears of side effects associated with the use of TCSs for AD should be recogn
AD ¼ atopic dermatitis.
Table 4 Consensus recommendations for antihistamines.
 A subset of patients with a mixture of AD and dermographism, allergic rhinitis, and
 Sedating antihistamines may be used short term, under supervision where itch of e
 There is insufﬁcient evidence to recommend the general use of antihistamines as pa
 Short-term, intermittent use of sedating antihistamines may be beneﬁcial in the setti
atopic dermatitis with topical therapies.
 Nonsedating antihistamines are not recommended as a routine treatment for at
rhinoconjunctivitis.
 The use of topical antihistamines for the treatment of patients with atopic dermatitivarieties of ﬁlaggrin gene mutations are present in Asia.15 Filaggrin
gene mutations as predisposing factors for AD have been reported
in Japanese patients,16 and evidence indicates that FLG P478S
polymorphism may confer susceptibility to the development of AD
among Taiwanese people.17
Emollients are crucial to restore skin barrier and the successful
management of AD. Emollients may contain both occlusives,
which provide a layer of lipid on the surface of the skin to slow
water loss and increase moisture content in the skin, and hu-
mectants, which are substances introduced into the stratum cor-
neum to increase its moisture retaining capacity.1,2,11 It is
commonly believed that emollients could restore the impaired
skin barrier function that is characteristic of AD. However, there
have only been a few well designed studies evaluating the efﬁcacy
of emollient therapy. The consensus recommendations for emol-
lients are listed in Table 2.
In a randomized, controlled trial involving 30 adults with mild-
to-moderate AD, 5 weeks of treatment with hydrolipidic cream
signiﬁcantly reduced the total body area affected, the itch score and
the Eczema Area and Severity Index score compared to vehicle onlyf AD
dry depending on the climate, moisture, or the use of air conditioning.
inﬂammatory agents, and also as maintenance therapy. Apply after swimming or
with AD as there is strong evidence that their use can reduce disease severity and
ever, there is no standard for the frequency or duration of bathing appropriate for
ents with AD.
agrance free) is recommended.
additives to bath water and the use of acidic spring water cannot be recommended
ed for patients with moderate to severe AD to decrease disease severity and water
od skin care and regular use of emollients alone. TCSs are effective and safe when
ﬂares are under control.
eatment of AD, including patient age, the location, severity and chronicity of the
t factors such as degree of xerosis, patient preference, and cost of medication.
ent of AD; however, evidence suggests that once-daily application of some corti-
ﬂamed eczema with oozing or chronic eczema with ﬁssures).
e treated.
reas that commonly ﬂare is recommended to help prevent relapses and is more
lamicepituitaryeadrenal axis suppression, should be considered, particularly in
ation for cutaneous side effects during long-term, potent steroid use is
nts with AD.
ized and addressed to improve adherence and avoid undertreatment.
bronchial asthma may beneﬁt from antihistamines.
czema causes sleep disturbance.
rt of the treatment of atopic dermatitis.
ng of sleep loss secondary to itch, but should not be substituted for management of
opic dermatitis in the absence of urticaria or other atopic conditions such as
s is not recommended because of the risk of absorption and of contact dermatitis.
Table 5 Consensus recommendations for therapeutic patient education.
 Disease nature
 Avoidance of irritants and allergens
 Treatment adherence should be emphasized at each consultation and should
encompass the following:
1. Appropriate treatment doses.
2. Treatment application frequency.
3. How to step up or step down treatment.
4. Management of infected eczema.
5. Information should be tailored to suit patients' cultural practices regarding
skin care and bathing.
6. Patients and caregivers should be informed that in patients with more
pigmented skin AD may temporarily cause the skin to lighten or darken.
C.-Y. Chu et al. / Dermatologica Sinica 33 (2015) 220e230 223control patients.18 Ceramide-based emollient therapy applied twice
daily for 3 weeks reduced pruritus and successfully improved AD
according to investigator global assessment in 58% of children aged
3 months to 16 years in an open-label community-based trial.19
Randomized and controlled trials are required to determine theTable 6 Consensus recommendations for topical calcineurin inhibitors (TCIs).
 TCIs are recommended and effective for acute and chronic treatment, along with m
selected clinical situations, such as recalcitrance to steroids, sensitive areas (e.g., fac
uninterrupted topical steroid use).
 Do not use TCIs under occlusion as this may enhance percutaneous absorption and
 Proactive, intermittent use of tacrolimus ointment as maintenance therapy on areas
need for topical corticosteroids, and is more effective than the use of emollients alo
 TCI may cause skin burning and pruritus, especially when applied to acutely inﬂamed
considered to minimize TCI application site reactions. Patients with AD should be co
 Routine blood monitoring of tacrolimus and pimecrolimus levels in patients with A
AD ¼ atopic dermatitis.
Table 7 Consensus recommendations for burst systemic corticosteroids.
 Although systemic steroids are used by some providers to treat AD because they rapid
is time-limited and judicious.
 Rebound ﬂare and increased disease severity is a commonly observed phenomenon
 Systemic steroids may be considered for short term (3e7 days) use in individual ca
optimized
 Burst systemic steroids may be considered for individuals with acute ﬂare-ups to ac
 Long term systemic steroids should generally be avoided in adults and children with A
beneﬁts.
Table 8 Consensus recommendations for phototherapy.
 Phototherapy treatment of all forms should be under the guidance and ongoing sup
 The light modality chosen should be guided by factors such as availability, cost, patie
 Phototherapy can be used as maintenance therapy in patients with chronic disease.
 Narrowband-UVB and UVA1 are the most frequently used efﬁcacious regimens in pa
acute ﬂares while narrowband-UVB in the management of chronic AD
 Caution should be used in the treatment of patients with fair skin phenotype, and p
 Because the long-term effects of phototherapy have not been elucidated, treatment s
AD ¼ atopic dermatitis.
Table 9 Consensus recommendations for topical and systemic antibiotics.
 Secondary infection should be suspected in patients with moderate to severe eczem
who are not responding to ﬁrst-line topical therapy.
 Topical antibiotic therapy may be appropriate for localized areas of infection.
 Systemic antibiotics are appropriate and can be recommended for use in patients wi
treatments for atopic dermatitis disease itself (which may include the concurrent us
non-infected atopic dermatitis is not recommended.
 In patients withmoderate to severe AD and clinical signs of secondary bacterial infecti
severity.
AD ¼ atopic dermatitis.optimal quantity and frequency of emollient therapy. The use of an
emollient as an adjunct to TCS therapy provides a steroid-sparing
alternative to single-agent TCS while minimizing the likelihood of
ﬂares.20e23 Patients should be advised on the quality, quantity and
frequency of moisturizers use required for maintaining skin barrier
function. Based on the skin characteristics and seasonal changes,
different galenic preparations of emollient might be indicated,
including ointments, creams, and lotions. For example, greasy
emollients are suitable for very dry skin in winter, while creamy
emollients are more suitable for dry skin in summer.1
Emollient therapy also includes the avoidance of irritating
cleansers, and using appropriate soap substitutes and/or emollient
additives when bathing or showering. Fragrances and preservatives
included in emollients may act as possible irritants. Therefore,
these ingredients deserve special consideration when particular
products are recommended.
Wet dressing or wet wrap therapy is useful technique along
with emollient therapy, but is not commonly practiced in health
care as it is a labor-intensive process for parents and patients.1 Wetaintenance, in both adults and children with AD, and are particularly useful in
e, anogenital, and skin folds), steroid-induced atrophy, or long-term
increase risk of immunosuppression, unless under physician's direction.
that commonly ﬂare is recommended to help prevent relapses while reducing the
ne.
skin. Initial treatment of patients with AD using topical corticosteroids should be
unseled about the possibility of these reactions.
D who are applying these agents is not recommended at this time.
ly improve clinical symptoms, caution is warranted to ensure their administration
upon discontinuation of systemic steroids.
ses whereas other systemic or phototherapy regimens are being initiated and/or
hieve rapid and effective symptomatic control.
D because the potential short- and long-term adverse effects largely outweigh the
ervision of a physician knowledgeable in phototherapy techniques.
nt skin type, skin cancer history, and patient use of photosensitizing medications.
tients with AD. Phototherapy with medium-dose UVA1 might be used to control
rior personal or family history of cutaneous malignancy.
hould be reserved for adults and children older than 12 years with recalcitrant AD.
a who have weeping dermatitis, folliculitis and overt clinical signs of infection, or
th clinical evidence of bacterial infections in addition to standard and appropriate
e of topical corticosteroids). The use of systemic antibiotics in the treatment of
on, bleach baths and intranasal mupirocinmay be recommended to reduce disease
Table 10 Consensus recommendations for systemic immunomodulatory agents.
 Systemic steroids may be considered for short term (3e7 days) use in individual cases whereas other systemic or phototherapy regimens are being initiated and/or
optimized
 Although systemic steroids are used by some providers to treat AD because they rapidly improve clinical symptoms, caution is warranted to ensure their administration
is time-limited and judicious.
 Rebound ﬂare and increased disease severity is a commonly observed phenomenon upon discontinuation of systemic steroids.
 Systemic immunosuppressive agents are indicated for the subset of adult and pediatric patients in whom optimized topical regimens and/or phototherapy do not
adequately control the signs and symptoms of disease, or in whom these treatment modalities are contraindicated. Systemic immunosuppressive agents may be
indicated in patients who are corticosteroid dependent.
 All immunosuppressive agents should be adjusted to the minimal effective dose once response is attained and sustained. Adjunctive therapies should be continued to
use the lowest dose and duration of systemic agent possible.
 Potential adverse effects are well documented for each immunosuppressive agent. Thus, patients receiving these systemic immunosuppressive agents should be
monitored for such potential consequences.
 Cyclosporine is effective and recommended as a treatment option for patients with AD refractory to conventional topical treatment.
 Azathioprine is recommended as a systemic agent for the treatment of refractory AD.
 Methotrexate is recommended as a systemic agent for the treatment of refractory AD. Folate supplementation is recommended during treatment with methotrexate.
 Mycophenolate mofetil may be considered as an alternative, variably effective therapy for refractory AD.
 Biological agents are emerging new treatments for AD, but limited data exist to determine the efﬁcacy of biological agents at this time.
AD ¼ atopic dermatitis.
Table 11 Consensus recommendations for antiseptics.
 Topical antiseptics (e.g. triclosan, benzalkonium chloride, chlorhexidine) in bath emollients are popular choices, particularly for children, and can reduce staphylococcal
colonization.
 Bleach baths may be helpful in cases of moderate to severe disease with frequent bacterial infections, and particularly for maintenance, as cultures did not show
clearance of the bacteria in the majority of patients.
 There is less concern about the development of bacterial resistance with use of dilute bleach relative to the use of topical and systemic antibiotics.
 Topical hypochlorite products are also available as an alternative to dilute bleach baths.
 Antiseptic bath products may aggravate atopic dermatitis due to irritant or allergic contact dermatitis and removal of normal commensal organisms.
Table 12 Consensus recommendations for alternative medicine.
 Patients and parents should be advised that complementary therapies have not undergone sufﬁcient evaluation of efﬁcacy or safety.
 Clinicians should enquire about and encourage patients to share information about any complementary therapies that are being used.
 Patients should be warned of possible contamination of so-called natural therapies with steroid medication.
 While traditional Chinese herbal medicine may be effective in the treatment of atopic dermatitis, to date, there is limited supporting evidence from well-designed
studies
C.-Y. Chu et al. / Dermatologica Sinica 33 (2015) 220e230224dressings involve two layers of open-weave tubular bandage that
are applied over topical preparations: a damp bottom layer, which
is applied directly over the topical preparation, and a dry top layer.1
These dressings occlude the affected area and lead to enhanced
absorption and reduced scratching by impeding contact with ﬁn-
gernails while providing a general soothing effect. Cold compresses
and wet dressings may be helpful to hydrate and sooth the skin. By
contrast, when used in conjunction with a TCS, wet dressings in-
crease steroid absorption, thus leading to an increased risk of
hypothalamicepituitaryeadrenal axis suppression and infection.1
Wet wraps are wet bandages wrapped over emollients and/or
topical steroid creams. Localized wet dressings (e.g., compresses)
are an important component of treatment for acute vesicular
eczema to enable cessation of the weeping lesions. In one study,
wet wraps were found to be as effective as topically applied oint-
ments in pediatric patients (aged 4e27 months) with moderate-to-
severe AD, but skin infections requiring antibiotic therapy were
more common and wet wraps were more difﬁcult to apply as
compared with conventional treatment.24
TCSs
TCSs exert anti-inﬂammatory, immunosuppressive and vasocon-
strictive properties and have also been shown to inhibit ﬁbroblast
activity. Numerous TCSs are available, and they range from low to
high potency.1,25 TCSs remain the ﬁrst-line mainstay treatment formoderate to severe AD.1,2,11 The efﬁcacy of TCSs is well established
in both adults and children with AD.26,27
Intermittent therapy, weekend therapy, and intermittent hot
spot therapy have been investigated as maintenance strategies due
to concerns regarding the prolonged use of TCSs. Previous studies
have conﬁrmed that an intermittent TCS regimen does not reduce
the efﬁcacy of such regimens.21,22,28 For example, one study found
that twice-weekly treatment with mometasone furoate 0.1% fatty
cream in stabilized lesion sites following acute ﬂares resulted in
90% of 68 adult AD patients remaining disease-free at 6 months.28
Topical ﬂuticasone propionate cream 0.05% has also demonstrated
efﬁcacy, with a low potential for local or systemic adverse effects
and only minimal effects on plasma or urinary cortisol.21,22 Over a
median exposure of 337 days, there were no reports of skin thin-
ning or atrophy with this regimen.21
When prescribing TCS therapy for AD patients, a cream base
should be used if the AD is weepy and inﬂamed, an ointment base
should be used if it is dry or licheniﬁed, and a lotion base is rec-
ommended in hair-bearing areas. Clear instructions should be
given to the patient regarding the quantity and duration of treat-
ment (e.g., 7e14 days for control of acute ﬂares). A TCS should be
applied only when there are active lesions and should be dis-
continued upon lesion clearance. An extended duration of use is
permitted when close supervision is ensured. Follow-up reassess-
ment is advised; if there is a ﬂare, retreatment with a TCS may be
required.
Figure 1 Algorithm of treatment for atopic dermatitis. NB ¼ narrowband.
C.-Y. Chu et al. / Dermatologica Sinica 33 (2015) 220e230 225Potential adverse effects of TCS therapy include skin atrophy,
telangiectasias, striae, steroid acne, rosacea, systemic absorption,
and hypothalamicepituitaryeadrenal suppression.29 However, ev-
idence from long-term studies suggests that ﬂuticasone propionate
0.05% cream or 0.05% ointment twice weekly is not associated with
signiﬁcant changes in skin thickness in children and adults with
moderate to severe chronic AD treated for up to 44 weeks.30,31
Similarly, no signiﬁcant differences were observed with regard to
serum cortisol levels with ﬂuticasone propionate.31 A retrospective
analysis of 100 cases of eczema herpeticum demonstrated that the
majority of infections occurred in patients with untreated AD,
arguing against the use of TCSs as a cause of this viral infection.32
Although colonization has been shown to be signiﬁcantly corre-
lated with disease severity in patients with exacerbation of mild to
severe AD, several studies found that Staphyloccocus aureus colo-
nization was signiﬁcantly reduced after TCS therapy.33e35 Children
may be more prone to systemic reactions given their higher ratio of
total body surface to bodyweight.29 The application of potent TCSs
should be avoided on the face, and in particular on the eyelids,
ﬂexures, and genital area. Different TCS preparations with different
age limits have been approved by the FDA. The consensus recom-
mendations for topical corticosteroids are listed as Table 3.
Antihistamines
Data from randomized controlled trials are available for both
sedating and nonsedating antihistaminesdthe results of these
trials generally suggest a limited role for antihistamines in the
treatment of AD. However, antihistamines may have a place in the
management of AD symptoms (e.g., pruritus) if urticarial features
are prominent. Sedating antihistamines may have particular utility
in children aged <2 years where sleep is an issue.1Preliminary data indicated a beneﬁcial effect of cetirizine in the
clearance of both signs and symptoms of AD in an 8-week double-
blind study in children aged 6e12 years.36 However, there was no
apparent beneﬁt for cetirizine (0.25 mg/kg twice daily) versus
placebo in a randomized, double-blind, controlled study of 817
infants aged 12e24 months on TCS therapy.37 Over a period of 18
months, disease severity was signiﬁcantly reduced in both study
arms (p < 0.001). Nevertheless, cetirizine displayed a steroid-
sparing effect through a reduction in the duration of moderate-
to-potent TCS use.37
Therapeutic patient education
Patient education has been shown to be essential and effective in
the management of AD. Patient education should include clear
explanations of the nature of AD (i.e., the pathogenesis and natural
course of the disease should be communicated in lay person lan-
guage), its aggravating factors and relieving factors and how short-
and long-term treatments can be used to help modify and manage
it. The short-term and long-term goals of therapy should be
established and reviewed regularly. It should also be clear to
caregivers how the different treatment modalities would help to
achieve the goals of therapy.
A comprehensive education program can improve children's
coping behavior, as well as parents' handling of their affected
children.38,39 Age-related structured educational programs may be
particularly useful in the long-term management of AD.40 Even
brief educational sessions have been shown to have a marked
therapeutic effect. One 30-minute education session with a
specialist dermatology nurse led to an 89% reduction in the severity
of AD.41 After successful education sessions, a ﬁve-fold increase in
the volume of emollients used was observed. In parents and
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of TCSs, stinging or itching caused by topical treatment, children
being uncooperative with treatment, and treatment being too time
consuming.1 Therefore, adherence, and ultimately successful
treatment, can be optimized by addressing these factors appro-
priately. Providing verbal and written information and giving
practical demonstrations of topical therapy applications and tech-
niques will typically lead to better patient understanding, accep-
tance and empowerment.
TCIs
The TCIs, including pimecrolimus and tacrolimus, are topical im-
munomodulators that have demonstrated beneﬁcial effects in
reducing the severity of AD. Topical tacrolimus is available as an
ointment for adults and children aged > 2 years, and pimecrolimus
is a cream available for adults and children aged > 2 years.1,2,11
Several guidelines recommend TCIs as a treatment option for
moderate-to-severe AD. TCIs may be useful in children requiring
long-term treatment or frequent use of mild TCSs for facial AD.1
TCIs have been shown to be effective in both the treatment and
prevention of ﬂares. Short-term studies of 4e6 weeks' duration
have shown that pimecrolimus is effective in childrenwithmild-to-
moderate AD.1,2,11 Previous studies have also conﬁrmed the efﬁcacy
of tacrolimus 0.03% ointment in children with mild to severe
AD.1,2,11 In adults with mild-to-moderate AD, pimecrolimus cream
1.0%, administered for 26 weeks at the ﬁrst signs and/or symptoms
of a subsequent recurrence, reduced the number of ﬂares requiring
TCS therapy.42 Pimecrolimus also demonstrated a steroid-sparing
effect, increasing the mean number of TCS-free days. However,
concomitant use of pimecrolimus and narrowband UVB is not
advisable in treating moderate to severe AD in children and ado-
lescents due to the lack of short-term additive therapeutic efﬁcacy
and potential concern of increased immunsuppression.43
Tacrolimus ointment can also be used for the proactive treat-
ment of AD.41 Twice-weekly application of tacrolimus 0.1% oint-
ment to normal appearing skin that has previously been affected by
eczema was shown to prevent, delay and even reduce the occur-
rence of ﬂares.44 Over a 12emonth period in adults with AD,
tacrolimus signiﬁcantly reduced the number of ﬂares requiring
substantial therapeutic intervention and the percentage of ﬂare
treatment days, while also increasing the time-to-ﬁrst ﬂare.44 In
Taiwan, an open-labeled, noncomparative, single-center study
showed a 90% improvement in AD after topical tacrolimus in both
adults and in children.45
A higher incidence of viral infections has been reported with
pimecrolimus usage. Skin infections reported to be associated with
pimecrolimus include varicella, herpes simplex, and eczema her-
peticum.1 Furthermore, in 2005, the United States Food and Drug
Administration issued a ‘black box’ warning for TCIs due to the lack
of long-term safety data and the potential risk of the development
of malignancies.46 This warning was based on several case reports
of lymphoma and skin cancer in patients treated with TCIs. How-
ever, there is currently no direct scientiﬁc evidence of an increased
risk for malignancy due to TCIs.1,11,47
A meta-analysis involving over 4000 patients in 25 randomized,
controlled trials reported that tacrolimus 0.1% was as effective as
moderate TCS therapy, an effect that was evident after 3 weeks of
treatment.48 Conversely, pimecrolimus was less effective than
betamethasone valerate 0.1%.
At present, there is a lack of direct comparative data among TCIs.
Furthermore, long-term studies demonstrating the safety of
tacrolimus and pimecrolimus are required before any recommen-
dations can be made indicating a preference for these agents over
TCS therapy.1 Topical tacrolimus may have particular clinical utilityin the long-term treatment of patients with resistant AD where
adverse effects from TCSs are likely to develop.48 Unlike TCSs, these
agents do not cause adverse effects of skin atrophy or folliculitis,
and can therefore be used on thinning skin and sensitive areas such
as the face.1
Clinical experience demonstrates that TCIs may be safely used as
therapy to prevent relapses and prolong remission when used for
2e4 weeks after the acute inﬂammation has settled with TCS use.
Consensus recommendations for topical calcineurin inhibitors are
listed in Table 6.
Systemic corticosteroids
Systemic corticosteroids are the most frequently used systemic
treatment for severe AD in routine care. Some clinicians ﬁnd them
useful as short-term therapy, i.e., for a maximum of up to 6 weeks,
in combinationwith other standard modalities such as TCSs or TCIs
(e.g., for acute ﬂares). However, oral corticosteroids are not rec-
ommended as a means to induce stable remission of AD or long-
term control because of well-documented side effects and the
high likelihood of relapse after short-term therapy.49 Consensus
recommendations for systemic corticosteroids are listed in Table 7.
Phototherapy
Phototherapy is a well-established treatment modality for severe
AD in both adults and children. It is widely used by dermatologists
in the management of severe AD. Common modes of phototherapy
include broadband UVB, narrowband UVB, photochemotherapy,
and high dose UVA1. Narrowband UVB and UVA1 are the most
frequently used efﬁcacious regimens in patients with AD.50,51
Phototherapy is a second-line treatment after failure of ﬁrst-line
treatment, and can be used as maintenance therapy in patients
with chronic disease.
While themechanism of action in phototherapy treatment of AD
has not been elucidated, UV is thought to have local anti-
inﬂammatory and immunosuppressive effects. A meta-analysis
study concluded that UV phototherapy is probably the most
effective treatment modality in AD, with signiﬁcant clinical
improvement evident as early as 2 weeks.51 In general, photo-
therapy has a rapid loss of effect once treatment is discontinued,
indicating that it is a good treatment for the management of acute
ﬂares. UVB phototherapy was found to reduce the overall body
surface area affected by AD.43 It has been recommended that
phototherapy with medium-dose (50 J/cm2) UVA1 should be used
to control acute ﬂares, while UVB modalities (e.g., narrowband
UVB, or NB-UVB) should be used in the management of chronic
AD.51e55 In a recent systematic review of phototherapy in AD,
Garritsen et al55 found 19 randomized controlled trials (RCTs) for
evaluating the effect of treatment with photo(chemo)therapy in
patients with AD. They conclude that both medium-dose UVA1 and
NB-UVB should be considered ﬁrst-choice treatment modalities.
UVA1 was initially introduced for the treatment of acute AD and
some guidelines do recommend UVA1 for the acute cases and NB-
UVB for the more chronic cases. However, based on the evidence
included in their review, they cannot conﬁrm these recommenda-
tions. For the decision-making in daily practice (whether prefer-
ence is given to UVA1 or NB-UVB), other considerations, such as
patient-reported outcomes, the availability of the treatment op-
tions and the duration of treatment, may play a role.55
In pediatric patients, there are some case series that have re-
ported beneﬁts from phototherapy in a percentage of patients.1
However, the use of phototherapy is generally not suitable for
children younger than 8 years as the long-term safety of photo-
therapy remains unknown. However, there is a potential for
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long-term risk of skin melanoma appears to be greater with PUVA
compared with UVB.50,51 It is important to identify which patients
are most likely to beneﬁt from phototherapy and to provide indi-
vidually tailored therapy to ensure optimal treatment outcomes.50
Consensus recommendations for phototherapy are listed in Table 8.
Topical and systemic antibiotics
Patients with AD can develop a secondary infectionwith a variety of
microbial organisms, including Staphylococcus, Streptococcus, her-
pes simplex virus, molluscum contagiosum virus, human papillo-
mavirus, and Malassezia furfur fungal infection. Infection with
S. aureus is the most common infectious complication of AD. It is
estimated that patients with AD carry S. aureus in 90% of clinically
affected areas and 75% of uninvolved areas.56 Staphylococcal
superantigens may penetrate the skin barrier and contribute to the
persistence and exacerbation of allergic skin inﬂammation in AD.57
Approximately 30% of the general population are also carriers, so
routine skin swabs from AD patients may not be helpful in differ-
entiating colonization from infection.56 AD that is infected and
oozing requires treatment with an antimicrobial or antiseptic.56
Topical antimicrobial therapy may be effective in the treatment of
localized infected AD; however, there is limited evidence for such
effectiveness from clinical studies.1,2,21
Flucloxacillin (dicloxacillin) is considered to be the ﬁrst-line
therapy for pediatric AD, but cephalexins may be preferred, espe-
cially in children.1 Clinicians should be familiar with local patterns
of antimicrobial resistance. Strains of S. aureus from AD children
had a high prevalence of methicillin-resistant S. aureus and multi-
drug resistance. Trimethoprimesulfamethoxazole, rifampin, fusi-
dic, acid and mupirocin appear to be more suitable for treatment
and decolonization of S. aureus in AD children.58 There is a sur-
prising lack of good evidence supporting use of systemic antibiotics
in the treatment of AD. However, clinical practice has shown that
long-term, low-dose antibiotics (i.e., cephalexin, trimethoprim/
sulphamethoxazole, erythromycin and tetracyclines), can be used
to treat recalcitrant eczema, with good effect.1 They have been
shown to decrease staphylococcal skin colonization and enhance
neutrophil activity. Consensus recommendations of using antibi-
otics for AD are listed in Table 9.
Systemic immunomodulatory agents
Systemic immunomodulatory agents are indicated and recom-
mended for the subset of adult and pediatric patients in whom
optimized topical regimens using emollients, topical anti-
inﬂammatory therapies, adjunctive methods, and/or photo-
therapy do not adequately control the signs and symptoms of dis-
ease. Systemic immunomodulating agents may also be used in
patients whose medical, physical, and/or psychological states are
greatly affected by their skin disease, which may include negative
impact on work, school performance, or interpersonal relation-
ships.1,12,59 The management of AD with systemic corticosteroids,
although used frequently and shown to temporarily suppress dis-
ease, should be avoided because of short- and long-term adverse
effects and an overall unfavorable risk-beneﬁt proﬁle. Short courses
of oral corticosteroids may lead to atopic ﬂares.12 Therefore,
cyclosporine has been recommended as a ﬁrst-line option in AD
refractory to conventional treatment.1,59 Patients with such cases
are better handled by experienced clinicians.
Cyclosporin can suppress cytokine expression and production
by T cells via inhibition of calcineurin. A systemic review of clinical
trials has shown cyclosporin to be the most consistently effective
treatment for adult and pediatric AD.12,60 For example, onerandomized, controlled trial used quality of life as the primary
outcome and found cyclosporin to be superior to placebo.61 In
head-to-head trials, cyclosporin was also found to be more efﬁca-
cious than prednisolone in causing the stable remission of atopic
dermatitis.62 Although higher doses (5 mg/kg of body weight) of
cyclosporin are more effective, lower starting doses (2.5 mg/kg of
body weight) with adjustment to the individual lowest effective
dose are preferable because most side effects are dose-related.1
Moreover, because of an increased risk for skin cancer, cyclo-
sporin therapy should not be combined with phototherapy. Ran-
domized controlled trials in both adults and children have
conﬁrmed that cyclosporin is effective in the short-term manage-
ment of severe AD at doses of 3e5 mg/kg/d. However, treatment is
limited by short-term side effects (e.g., nausea and paresthesia) and
long-term side effects (e.g. hypertension, renal impairment, and
cutaneous changes), and by frequent rebound after cessation of
therapy. Treatment with mycophenolate mofetil, a purine biosyn-
thesis inhibitor with immunosuppressive effects, at doses of up to
2 g/d has been reported to have efﬁcacy in uncontrolled studies in
adults with severe AD and those with widespread refractory
AD.63,64
Both methotrexate (10e22.5 mg/wk) and azathioprine
(1.5e2.5 mg/kg/d) have demonstrated clinically relevant improve-
ments in severe AD, and are relatively well tolerated in the short
term.12,65 In a small comparative study (n ¼ 42), similar clinical
improvements were observed with these two agents, with
approximately 40% of patients demonstrating a reduction in the
severity of AD after 12 weeks and 24 weeks of treatment. While
hematological abnormalities were more common with azathio-
prine, no serious adverse events occurred with either agent.65
Disease severity was reduced within 3 months of use, and signiﬁ-
cant improvements were noted for pruritus (p¼ 0.001) and dryness
(p ¼ 0.033). Adverse hematological and biochemical effects
appeared to be acceptable although longer-term monitoring is
advised.66
Omalizumab is a humanized monoclonal anti-IgE antibody that
limits the release of mediators of the allergic response by reducing
the surface-bound IgE on its high-afﬁnity receptor on mast cells
and basophils, and also by reducing high afﬁnity IgE receptor
expression on basophils and tracheobronchial submucosal gland
cells.67 Although there are many case series showing the effects of
omalizumab in AD, the role and efﬁcacy of omalizumab in the
treatment of AD may need more placebo-controlled prospective
trials to clarify.67,68
Consensus recommendations for systemic therapies are listed in
Table 10.Antiseptics
Topical antiseptics (e.g., triclosan, benzalkonium chloride, chlor-
hexidine) in bath emollients are popular choices, particularly for
children, and can reduce staphylococcal colonization.1 However,
topical antiseptics have a limited role in the management of AD.
There are two mechanisms by which antiseptic bath products may
aggravate AD: irritation and removal of normal commensal or-
ganisms. There are several reports of irritant or allergic contact
dermatitis involving the neck, axilla, popliteal and antecubital
fossa, and anogential area resulting from such products.69e71
The chronic use of diluted bleach baths has been shown to be
effective in patients with AD who have clinical signs of a secondary
bacterial infection.72 In a randomized, investigator-blinded, pla-
cebo-controlled study in 31 patients receiving oral cephalexin for
14 days and emollient therapy for 3 months, bleach baths twice
weekly reduced the severity of AD and were well tolerated with no
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antiseptic therapy are listed in Table 11.
Alternative medicine
Complementary and alternative therapies are commonly used for
AD.73e75 In a secondary care UK-based survey, almost 50% of par-
ents of children with AD were using current complementary ther-
apies, with a further one third reporting that they planned to use
them in the future.76 Traditional Chinese medicine (TCM), as a
whole medical system of complementary and alternative medicine,
is popular in Taiwan. TCM treatment for AD is based on the prin-
ciples of heat-clearing, dampness-elimination, blood-cooling and
moistening.77,78 Ethnicity, belief that complementary treatments
were safer, and a belief that traditional therapies were not working
were given as reasons for the use of complimentary therapies. A
placebo effect is highly probable in these reports, although
adequate controlled studies are lacking.
Probiotics
The use of probiotics, which may modulate the immune system,
represents a novel treatment for AD. Current evidence on the efﬁ-
cacy of probiotics in AD is inconsistent, and data are inadequate and
inconsistent to support the use of these treatments in children or
adults with AD.79e82
In infants aged 6e18 months with moderate to severe AD,
supplementation with the probiotic Lactobacillus fermentum VRI-
003 PCC improved the extent and severity of the disease.79 Evi-
dence from a small study in infants reported a signiﬁcant
improvement in skin condition with probiotic-supplemented for-
mulas.80 Probiotics have also been shown to be effective in the
primary prevention of AD. Prenatal Lactobacillus GG reduced the
frequency of atopic eczema by 50% in children aged 2 years who
were at risk of developing AD.83 However, a number of studies have
failed to demonstrate any beneﬁts. In infants with moder-
ateetoesevere AD, probiotics did not provide any additional
improvement over standard therapy.81 A double-blind prospective
trial also reported no beneﬁcial effect of probiotic supplementation
with Lactobacillus GG in pregnancy or early infancy for the pre-
vention or treatment of AD.82
Furthermore, there are often considerable differences in the
strains and dosages of various probiotics. Therefore, results sup-
porting the efﬁcacy of a particular formulation may not be appli-
cable to probiotics in general.
TCM
The use of TCM treatments for AD has become popular due to the
side effects of current conventional treatments.73e78 While TCM
may be effective in the treatment of AD, to date there is limited
supporting evidence from well-designed studies.84e87 A Cochrane
review reported heterogeneous results based on four poorly
designed studies of Zemaphyte, which is no longer being manu-
factured.86 This particular TCM improved erythema, skin surface
damage, sleep disturbance, and itching, although adverse effects
were not well described. At a major hospital in Taiwan, a cross-
sectional survey of 4145 patients showed that 2841 (68.54%)
chose TCM only, while 1304 (31.46%) chose to combine TCM and
western medicine therapies. Among the 87,573 prescriptions
written for Chinese medicine, the most frequently prescribed
herbal formula and single herb were Xiao-Feng-San (Eliminate
Wind Powder; 16.98%) and Bai-Xian-Pi (Cortex Dictamni; 12.68%),
respectively.85 In a prospective, randomized, double-blind, pla-
cebo-controlled trial, 71 patients with severe intractable atopic
dermatitis were given an 8-week treatment with oral Xiao-Feng-
San (47 patients) or placebo (24 patients). The results showedthat Xiao-Feng-San formula might improve lesion scores, pruritus
symptoms and sleep conditions.88
Following reports of a possible association between liver dam-
age and TCM, liver function should be monitored in patients using
TCM for AD.89 There is also a case report of severe cardiomyopathy
following a 2-week course of TCM in the form Chinese herbal tea.90
Consensus recommendations for complementary therapy are listed
in Table 12.Summary
Optimal AD management may be inﬂuenced by the different
healthcare systems, variable access to medical care, climates, and
cultural diversity. The frequency and severity of AD is also signiﬁ-
cantly inﬂuenced by environmental and cultural factors, as well as
dietary intake.
TCS therapy in conjunction with long-term emollient-based
therapy is the mainstay of AD management. TCS therapy has an
important role in the treatment of AD and should be initiated early
in the course of the disease. TCIs have been shown to be effective in
both the treatment and prevention of ﬂares. Short-term studies of
4e6 weeks' duration have shown that TCIs are effective and well
tolerated. TCIs may also be safely used as therapy to prevent re-
lapses and prolong remission after TCS use.
Wet dressings or wet wraps are effective in the treatment of
moderate-to-severe oozing AD. However, their usefulness may be
limited by the humid climate in Taiwan, which makes this a less
popular form of therapy.1 Systemic immunomodulatory therapy
should generally be reserved for severe and refractory AD when
other therapies have failed. Phototherapy has been shown to be
highly effective in reducing disease severity in AD. Meanwhile,
there is inconsistent evidence to support the use of complementary
therapies in the treatment of patients with AD.
The management of AD may be challenging. Dermatologists
should emphasize the use of emollient-based therapy in combi-
nation with TCS therapy.1Acknowledgments
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